Video
Author(s):
Yi Lin, MD, PhD, discusses CAR T-cell therapy–related toxicities in multiple myeloma.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Yi Lin, MD, PhD, consultant, Division of Hematology, Department of Internal Medicine, consultant, Division of Experimental Pathology and Laboratory Medicine, Department of Laboratory Medicine and Pathology, assistant professor of medicine and oncology, Mayo Clinic, discusses CAR T-cell therapy–related toxicities in multiple myeloma.
In multiple myeloma, investigational CAR T-cell therapy products do not appear to induce the same degree of severe toxicities as in other hematologic malignancies, explains Lin. For example, as demonstrated in several clinical trials, less than 10% of patients typically develop grade 3 or higher cytokine release syndrome or neurotoxicity that would require monitoring in the intensive care unit, says Lin.
Notably, some contributing factors to this lesser degree of severe toxicities could be the design of the CAR T-cell products, along with the natural aspects of the disease. The field is now trying to gain a greater understanding on how to best utilize interventions, such as tocilizumab (Actemra) and steroids, to retain response while preventing severe toxicities, concludes Lin.
Drs Al Malki and Auletta on PTCy GVHD Prophylaxis in Patients With HLA-UUMD
Tivozanib Elicits Similar PROs With or Without Nivolumab in Advanced Clear Cell RCC
Nivolumab Plus Cabozantinib Provides Durable Benefit in First-Line Advanced RCC
CBM588 Plus Cabozantinib/Nivolumab Shows Early Activity in Metastatic Renal Cell Carcinoma
Tivozanib Elicits Similar PROs With or Without Nivolumab in Advanced Clear Cell RCC
Nivolumab Plus Cabozantinib Provides Durable Benefit in First-Line Advanced RCC
CBM588 Plus Cabozantinib/Nivolumab Shows Early Activity in Metastatic Renal Cell Carcinoma
Cabozantinib Plus Nivolumab/Ipilimumab Sustains PFS Benefit in Advanced RCC
2 Commerce Drive
Cranbury, NJ 08512